Blog
RSS FeedPosted by Michael Wonder on 02 Jun 2021
The economics of alternative payment models for pharmaceuticals
1 June 2021 - Pharmaceuticals are priced uniformly by convention, but vary in their degree of effectiveness for different disease indications. ...
Posted by Michael Wonder on 31 May 2021
External reference pricing: the drug pricing reform America needs?
27 May 2021 - External reference pricing, sometimes known as international reference pricing, refers to the practice of informing price negotiations ...
Posted by Michael Wonder on 25 May 2021
ICER publishes protocol for first annual assessment of drug coverage policies that present barriers to fair access
25 May 2021 - ICER’s analysis, based on MMIT’s market access analytics solution, will evaluate how 15 of the largest ...
Posted by Michael Wonder on 17 May 2021
Quality, access, and the use of real world data by payers: where are we now? Where do we want to be in the future?
15 May 2021 - One of the biggest challenges payers face today is determining the value of innovative therapies in diseases ...
Posted by Michael Wonder on 14 May 2021
Making cancer treatments affordable today won’t hurt tomorrow’s innovation
12 May 2021 - Congress is about to debate legislation—the Lower Drug Costs Now Act (H.R.3)—that would give Medicare the ...
Posted by Michael Wonder on 14 May 2021
ICER releases draft evidence report on therapies for atopic dermatitis
14 May 2021 - Public comment period now open until 11 June 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 07 May 2021
Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States ...
Posted by Michael Wonder on 06 May 2021
ICER to assess treatment for severe asthma
6 May 2021 - Report will be subject of Midwest CEPAC meeting in November 2021; draft scoping document open to ...
Posted by Michael Wonder on 05 May 2021
ICER releases draft evidence report on aducanumab for Alzheimer’s disease
5 May 2021 - Given the risk of side effects and the uncertainty of benefit, ICER assigns a draft rating of ...
Posted by Michael Wonder on 29 Apr 2021
ISPOR launches HEOR solutions centre
27 April 2021 - New resource offers easy access to HEOR expertise from leading companies in the field. ...
Posted by Michael Wonder on 26 Apr 2021
ICER publishes white paper evaluating policy options to strengthen FDA’s accelerated approval pathway for prescription drugs
26 April 2021 - Informed by expert input from patient groups, former regulators, payers, and life science companies, white paper analyses ...
Posted by Michael Wonder on 16 Apr 2021
ICER publishes final evidence report and policy recommendations on therapies for lupus nephritis
16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both ...
Posted by Michael Wonder on 13 Apr 2021
New recommendations on the critical appraisal of systematic reviews with cost and cost effectiveness outcomes
13 April 2021 - ISPOR announced today the publication of new guidance on how to evaluate the quality and risk ...
Posted by Michael Wonder on 12 Apr 2021
International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects
12 April 2021 - Many countries use international (or external) reference pricing—benchmarking prices against those in other countries—to manage spending ...
Posted by Michael Wonder on 12 Apr 2021
ICER publishes research protocol for assessing the unsupported price increases on prescription drugs that occurred in 2020
12 April 2021 - Final assessment to be published on 16 November; through 10 May, ICER is accepting public Input ...